Literature DB >> 23599669

Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto).

Zachary Stacy.   

Abstract

Entities:  

Keywords:  anticoagulant; apixaban; dabigatran; deep vein thrombosis; orthopedic surgery; pulmonary embolism; rivaroxaban; total hip replacement; total knee replacement; venous thromboembolism

Year:  2013        PMID： 23599669      PMCID： PMC3628174     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  32 in total

1.  Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Meyer Michel Samama; Jean-Luc Martinoli; Léna LeFlem; Céline Guinet; Geneviève Plu-Bureau; François Depasse; Elisabeth Perzborn
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

2.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

3.  Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty.

Authors:  Michael A Mont; Joshua J Jacobs; Lisa N Boggio; Kevin John Bozic; Craig J Della Valle; Stuart Barry Goodman; Courtland G Lewis; Adolph J Yates; William Charles Watters; Charles M Turkelson; Janet L Wies; Patrick Donnelly; Nilay Patel; Patrick Sluka
Journal:  J Am Acad Orthop Surg       Date:  2011-12       Impact factor: 3.020

4.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

5.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Philip Hornick
Journal:  Lancet       Date:  2010-03-06       Impact factor: 79.321

6.  Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.

Authors:  R J Friedman; G A Dunsworth
Journal:  Clin Orthop Relat Res       Date:  2000-01       Impact factor: 4.176

Review 7.  Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis.

Authors:  Ross I Baker; Paul B Coughlin; Alex S Gallus; Paul L Harper; Hatem H Salem; Erica M Wood
Journal:  Med J Aust       Date:  2004-11-01       Impact factor: 7.738

Review 8.  Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors:  Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Authors:  Michael Rud Lassen; Gary E Raskob; Alexander Gallus; Graham Pineo; Dalei Chen; Ronald J Portman
Journal:  N Engl J Med       Date:  2009-08-06       Impact factor: 91.245
View more
  1 in total

1.  Direct Oral Anticoagulants in the Prevention of Venous Thromboembolism Following Surgery for Hip Fracture in Older Adults: A Population-Based Cohort Study.

Authors:  En Lin Goh; Pratha Kumari Gurung; Shaocheng Ma; Timothy Pilpel; James Henderson Dale; Angela Kannan; Sambandam Anand
Journal:  Geriatr Orthop Surg Rehabil       Date:  2020-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.